Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;7(5):1403-1407.
doi: 10.3892/etm.2014.1574. Epub 2014 Feb 21.

Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients

Min Zhao  1 , Hongbing Li  1 , Lei Li  1 , Yijie Zhang  1
Affiliations

Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients

Min Zhao et al. Exp Ther Med. 2014 May.

Abstract

The aim of the present study was to investigate the effects of a gemcitabine plus platinum (GP) regimen combined with dendritic cell-cytokine induced killer (DC-CIK) immunotherapy on the recurrence and survival rate in patients with non-small cell lung cancer (NSCLC). Patients (n=157) with stage III NSCLC that had received surgery were randomly divided into a control group and an observation group. The control group was administered with a GP regimen and the observation group received GP chemotherapy that was based on DC-CIK cell immunotherapy in addition to SC-CIK cell immunotherapy here. The two groups were followed up for 36 months and their postoperative cellular immune function, disease-free survival time, cumulative recurrence rate and cumulative survival rate was analyzed. The percentages of CD3+CD4+ T lymphocytes, natural killer cells and the CD4/CD8 ratio were identified to be significantly increased following treatment compared with those observed prior to treatment in the control and observation groups; conversely, the CD3+CD8+ T lymphocyte percentage decreased significantly (P<0.05). Furthermore, the results of the patients in the observation group were significantly better compared with the control group based on these indicators (P<0.05). The median disease-free survival time of patients in the observation group (28 months) was identified to be significantly longer than that of the control group (22 months; P<0.05), the three-year cumulative recurrence rate in the observation group (47.37%) was significantly lower than that of the control group (76.92%; P<0.05) and the three-year cumulative survival rate of the patients in the observation group (58.23%) was significantly higher than that of the control group patients (37.14%; P<0.05). In conclusion, the GP regimen combined with DC-CIK immunotherapy significantly improved the immune cell function in the postoperative NSCLC patients, in addition to reducing postoperative tumor recurrence and prolonging the survival time of patients with NSCLC.

Keywords: dendritic cell-cytokine induced killer cell therapy; gemcitabine plus platinum regimen; non-small cell lung cancer; recurrence rate; survival rate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Phenotypic analysis of dendritic and cytokine induced killer cells in vitro. (A) Cell surface markers, CD80, 83. (B) Cell surface markers, CD1α and HLA-DR. (C) Cell surface marker, CD86. (D) CD3+CD56+ and CD3+CD8+ double positive cells. CD, cluster of differentiation; HLA-DR, human leukocyte antigen-DR. CD, cluster of differentiation; HLA-DR, human leukocyte antigen-DR.
Figure 2
Figure 2
Comparison of cell immune function in the control and observation groups prior to and following treatment. (A) CD3+CD4+ T lymphocytes. (B) CD3+CD8+ T lymphocytes. (C) CD4/CD8 ratio. (D) CD56+ natural killer cells. *P<0.05 compared with before treatment and #P<0.05 compared with the control group after treatment.
Figure 3
Figure 3
Comparison of (A) cumulative recurrence rate and (B) survival rate in the control and observation groups.
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. - PubMed
    1. Goldstraw P, Ball D, Jett JR, Le Chevalier T, Lim E, Nicholson AG, Shepherd FA. Non-small-cell lung cancer. Lancet. 2011;378:1727–1740. - PubMed
    1. Naim Younes R, Gross JL, Abrao FG, Rodrigues Pereira J. Impact of adjuvant chemotherapy in completely resected stage IIIA non-small cell lung cancer. Minerva Chir. 2013;68:169–174. - PubMed
    1. Filipits M, Pirker R. Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer. 2011;74:355–363. - PubMed
    1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30. - PubMed

LinkOut - more resources